Zealand Pharma AS
Company Profile
Business description
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Contact
Sydmarken 11
SoborgDK-2860
DNKT: +45 88773600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
578
Stocks News & Analysis
stocks
Long term outlook intact for wide moat income share
stocks
ASX rare earths play looks to expand production
stocks
Anthropic’s leaked financials reflect fast growth, but not a $2 trillion valuation
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,894.60 | 8.90 | -0.10% |
| CAC 40 | 7,761.42 | 103.65 | -1.32% |
| DAX 40 | 25,067.12 | 382.07 | -1.50% |
| Dow JONES (US) | 51,001.47 | 519.81 | -1.01% |
| FTSE 100 | 10,458.69 | 83.00 | -0.79% |
| HKSE | 24,130.50 | 150.06 | -0.62% |
| NASDAQ | 27,403.99 | 195.89 | -0.71% |
| Nikkei 225 | 70,035.71 | 648.27 | -0.92% |
| NZX 50 Index | 13,684.04 | 16.08 | -0.12% |
| S&P 500 | 7,774.91 | 44.02 | -0.56% |
| S&P/ASX 200 | 8,727.70 | 8.00 | -0.09% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |